Advertisement

Eosinophile Entzündung der Atemwege: Fokus auf Asthma und COPD

  • M. Lommatzsch
Leitthema
  • 19 Downloads

Zusammenfassung

Die Bestimmung der Bluteosinophilen gewinnt im Rahmen der Diagnostik und der Therapieplanung eines Asthma immer mehr an Bedeutung. Die aktuelle Asthma-Leitlinie empfiehlt daher, bei Patienten mit Asthma oder Asthmaverdacht die Bluteosinophilen mindestens an zwei unterschiedlichen Zeitpunkten zu bestimmen. Bei der chronisch obstruktiven Lungenerkrankung (COPD) ist hingegen die Bedeutung der Eosinophilenkonzentration als Prädiktor für ein Ansprechen von inhalativen Kortikosteroiden (ICS) oder Biologika noch nicht abschließend geklärt. Daher kann eine Implementierung des Differenzialblutbilds mit Messung der Bluteosinophilen für die COPD-Praxis noch nicht empfohlen werden.

Schlüsselwörter

Eosinophile Blut Leitlinie Chronische obstruktive Lungenerkrankung Biologika 

Eosinophilic inflammation of the airways: focus on asthma and COPD

Abstract

The clinical relevance of the determination of blood eosinophils for the diagnosis and treatment of asthma has increased in recent years. Therefore, current asthma guidelines recommend measuring blood eosinophils at least twice (at different time points) in patients with asthma or suspected asthma. In contrast, the relevance of the blood eosinophil concentration as a predictor of the response to inhalative corticosteroids (ICS) or biologics in chronic obstructive pulmonary disease (COPD) is incompletely understood. Thus, the implementation of a differential blood pattern with routine measurement of blood eosinophils in COPD is currently not recommended.

Keywords

Eosinophils Blood Guidelines Chronic obstructive pulmonary disease Biologics 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Lommatzsch erhielt Honorare für Beratungen und Vorträge von den Firmen ALK Abelló, Allergopharma, Astra Zeneca, Bencard, Berlin-Chemie, Boehringer-Ingelheim, Boston Scientic, Chiesi, Circassia, GSK, Janssen-Cilag, MSD, Mundipharma, Novartis, Nycomed/Takeda, Sanofi, TEVA, UCB. Er erhielt Forschungsförderung von der Deutschen Forschungsgemeinschaft (DFG), dem Land Mecklenburg-Vorpommern, GSK, AstraZeneca.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Rackemann FM (1918) A clinical study of one hundred and fifty cases of bronchial asthma. Arch Intern Med 12:517–552CrossRefGoogle Scholar
  2. 2.
    Lai K, Chen R, Peng W, Zhan W (2017) Non-asthmatic eosinophilic bronchitis and its relationship with asthma. Pulm Pharmacol Ther 47:66–71CrossRefPubMedGoogle Scholar
  3. 3.
    Thomson NC, Chaudhuri R (2004) Why is eosinophilic bronchitis not asthma? Am J Respir Crit Care Med 170:4–5CrossRefPubMedGoogle Scholar
  4. 4.
    Knutsen AP, Bush RK, Demain JG et al (2012) Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 129:92–93CrossRefGoogle Scholar
  5. 5.
    Agarwal R, Khan A, Aggarwal AN et al (2011) Clinical relevance of peripheral blood eosinophil count in allergic bronchopulmonary aspergillosis. J Infect Public Health 4:235–243CrossRefPubMedGoogle Scholar
  6. 6.
    Pavord ID, Beasley R, Agusti A et al (2018) After asthma: redefining airways diseases. Lancet 391:350–400CrossRefPubMedGoogle Scholar
  7. 7.
    Lambrecht BN, Hammad H (2015) The immunology of asthma. Nat Immunol 16:45–56CrossRefPubMedGoogle Scholar
  8. 8.
    Yancey SW, Keene ON, Albers FC et al (2017) Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol 140:1509–1518CrossRefPubMedGoogle Scholar
  9. 9.
    Wagener AH, de Nijs SB, Lutter R et al (2015) External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 70:115–120CrossRefPubMedGoogle Scholar
  10. 10.
    Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG (2014) Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 11:531–536CrossRefPubMedGoogle Scholar
  11. 11.
    Lommatzsch M, Stoll P (2016) Novel strategies for the treatment of asthma. Allergo J Int 25:11–17CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nair P, Pizzichini MM, Kjarsgaard M et al (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360:985–993CrossRefPubMedGoogle Scholar
  13. 13.
    Buhl R, Bals R, Baur X et al (2017) Guideline for the Diagnosis and Treatment of Asthma – Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology. Pneumologie 71:849–919CrossRefPubMedGoogle Scholar
  14. 14.
    McGrath KW, Icitovic N, Boushey HA et al (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185:612–619CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Price DB, Rigazio A, Campbell JD et al (2015) Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 3:849–858CrossRefPubMedGoogle Scholar
  16. 16.
    van Huisstede A, Rudolphus A, Castro Cabezas M et al (2015) Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax 70:659–667CrossRefPubMedGoogle Scholar
  17. 17.
    Brown HM (1958) Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 2:1245–1247CrossRefPubMedGoogle Scholar
  18. 18.
    Brown HM, Storey G, George WH (1972) Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1:585–590CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    FitzGerald JM, Bleecker ER, Menzies-Gow A et al (2018) Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 6:51–64CrossRefPubMedGoogle Scholar
  20. 20.
    Lommatzsch M (2016) Treatment of refractory asthma with antibodies. Dtsch Med Wochenschr 141:790–793CrossRefPubMedGoogle Scholar
  21. 21.
    Castro M, Corren J, Pavord ID et al (2018) Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 378(26):2486–2496.  https://doi.org/10.1056/NEJMoa1804092 CrossRefPubMedGoogle Scholar
  22. 22.
    Humbert M, Taille C, Mala L, Le Gros V, Just J, Molimard M (2018) Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 51(5):1702523.  https://doi.org/10.1183/13993003.02523-2017 CrossRefPubMedGoogle Scholar
  23. 23.
    Casale TB, Luskin AT, Busse W et al (2018) Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract pii:S2213-2198(18)30323-4.  https://doi.org/10.1016/j.jaip.2018.04.043 Google Scholar
  24. 24.
    Evans PM, O’Connor BJ, Fuller RW, Barnes PJ, Chung KF (1993) Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J Allergy Clin Immunol 91:643–650CrossRefPubMedGoogle Scholar
  25. 25.
    Hogg JC, Chu F, Utokaparch S et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653CrossRefPubMedGoogle Scholar
  26. 26.
    Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG (2016) Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 193:965–974CrossRefPubMedGoogle Scholar
  27. 27.
    Brusselle G, Pavord ID, Landis S et al (2018) Blood eosinophil levels as a biomarker in COPD. Respir Med 138:21–31CrossRefPubMedGoogle Scholar
  28. 28.
    Bafadhel M, Pavord ID, Russell REK (2017) Eosinophils in COPD: just another biomarker? Lancet Respir Med 5:747–759CrossRefPubMedGoogle Scholar
  29. 29.
    Yun JH, Lamb A, Chase R et al (2018) Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 141(e10):2037–2047CrossRefPubMedGoogle Scholar
  30. 30.
    Casanova C, Celli BR, de-Torres JP et al (2017) Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 50(5): 1701162.  https://doi.org/10.1183/13993003.01162-2017 CrossRefPubMedGoogle Scholar
  31. 31.
    Hastie AT, Martinez FJ, Curtis JL et al (2017) Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med 5:956–967CrossRefPubMedGoogle Scholar
  32. 32.
    Brightling CE, Bleecker ER, Panettieri RA Jr. et al (2014) Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2:891–901CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Buhl R, Criee CP, Kardos P et al (2016) A year in the life of German patients with COPD: the DACCORD observational study. Int J Chron Obstruct Pulmon Dis 11:1639–1646CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Greulich T, Vogelmeier CF (2018) Blood eosinophils as a marker of eosinophilic exacerbations in COPD. Lancet Respir Med 6:e17CrossRefPubMedGoogle Scholar
  35. 35.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID (2015) Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3:435–442CrossRefPubMedGoogle Scholar
  36. 36.
    Siddiqui SH, Guasconi A, Vestbo J et al (2015) Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 192:523–525CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Watz H, Tetzlaff K, Wouters EF et al (2016) Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 4:390–398CrossRefPubMedGoogle Scholar
  38. 38.
    Lipson DA, Barnhart F, Brealey N et al (2018) Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 378:1671–1680CrossRefPubMedGoogle Scholar
  39. 39.
    Papi A, Vestbo J, Fabbri L et al (2018) Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 391:1076–1084CrossRefPubMedGoogle Scholar
  40. 40.
    Pavord ID, Chanez P, Criner GJ et al (2017) Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med 377:1613–1629CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung für Pneumologie und Internistische Intensivmedizin, Zentrum für Innere MedizinUniversitätsmedizin RostockRostockDeutschland

Personalised recommendations